Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer? M. Alexander Otto, PA, MMSc June 24, 2026

https://www.medscape.com/viewarticle/expert-q-drug-holiday-metastatic-prostate-cancer-2026a1000ld3?src= Once men with metastatic hormone-sensitive prostate cancer start androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI), the conventional thinking is that they stay on them indefinitely. But treatment comes at the cost of considerable side effects, including fatigue, hot flashes, sexual problems, weight gain, and others. Their use has also been associated with increased risks for cardiovascular disease, osteoporosis, and depression.